John M Kane

Summary

Affiliation: Long Island Jewish Medical Center
Country: USA

Publications

  1. ncbi Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications
    David Straker
    Department of Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY, USA
    Am J Psychiatry 162:1217-21. 2005
  2. ncbi Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
  3. ncbi Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 8:19. 2008
  4. ncbi Progress defined--short-term efficacy, long-term effectiveness
    J Kane
    Department of Psychiatry, Long Island Jewish Medical Center, New York, USA
    Int Clin Psychopharmacol 16:S1-8. 2001
  5. ncbi The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, New York, NY, USA
    Schizophr Res 105:208-15. 2008
  6. ncbi Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 65:16-20. 2004
  7. ncbi Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Albert Einstein College of Medicine, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 167:181-9. 2010
  8. ncbi An evidence-based strategy for remission in schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 69:25-30. 2008
  9. ncbi Atypical antipsychotics: sedation versus efficacy
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 69:18-31. 2008
  10. ncbi Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychopharmacol 28:S29-35. 2008

Research Grants

  1. PROSPECTIVE STUDY OF TARDIVE DYSKINESIA DEVELOPMENT
    John Kane; Fiscal Year: 2001
  2. PREVENTING MORBIDITY IN FIRST EPISODE SCHIZOPHRENIA
    John Kane; Fiscal Year: 2001
  3. Treating Refractory Childhood Schizophrenia
    John Kane; Fiscal Year: 2004
  4. Relapse Prevention Study: Steering and Implementation
    John Kane; Fiscal Year: 2007

Detail Information

Publications115 found, 100 shown here

  1. ncbi Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications
    David Straker
    Department of Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY, USA
    Am J Psychiatry 162:1217-21. 2005
    ..The authors' goal was to explore the relationship between second-generation antipsychotics and the metabolic syndrome...
  2. ncbi Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
    ..To identify a simple decision tree using early symptom change to predict response to atypical antipsychotic therapy in patients with (Diagnostic and Statistical Manual, Fourth Edition, Text Revised) chronic schizophrenia...
  3. ncbi Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 8:19. 2008
    ..This study compared the costs of antipsychotic polypharmacy for patients who initiated on 1 of the 3 most commonly prescribed atypical antipsychotics - olanzapine, quetiapine, or risperidone...
  4. ncbi Progress defined--short-term efficacy, long-term effectiveness
    J Kane
    Department of Psychiatry, Long Island Jewish Medical Center, New York, USA
    Int Clin Psychopharmacol 16:S1-8. 2001
    ..These drugs may, therefore, provide clinicians with a new and important addition for first-line management of schizophrenia...
  5. ncbi The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, New York, NY, USA
    Schizophr Res 105:208-15. 2008
    ..To examine the efficacy of aripiprazole across symptoms in patients with acute exacerbation of schizophrenia or schizoaffective disorder...
  6. ncbi Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 65:16-20. 2004
    ..This article will review studies of the prevalence and incidence of tardive dyskinesia in patients taking antipsychotic agents...
  7. ncbi Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Albert Einstein College of Medicine, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 167:181-9. 2010
    ..The purpose of the present study was to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatment of schizophrenia...
  8. ncbi An evidence-based strategy for remission in schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 69:25-30. 2008
    ..This article briefly reviews the status of remission as a therapeutic goal in the treatment of schizophrenia and summarizes available treatment research reporting remission and recovery as clinical outcomes...
  9. ncbi Atypical antipsychotics: sedation versus efficacy
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 69:18-31. 2008
    ....
  10. ncbi Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychopharmacol 28:S29-35. 2008
    ..4 msec (haloperidol) at end point. Iloperidone demonstrated long-term efficacy equivalent to haloperidol and a favorable long-term safety profile, potentially making this agent a suitable option as maintenance therapy for schizophrenia...
  11. ncbi PORT recommendations
    John M Kane
    Psychiatric Research, Long Island Jewish-Hillside Medical Center, 75-59 263rd St, Glen Oaks, NY 11004, USA
    Schizophr Bull 30:605-7. 2004
  12. ncbi Treatment strategies to prevent relapse and encourage remission
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 68:27-30. 2007
    ..Therefore, achieving the goals of remission and recovery is in the best interest not only of patients with schizophrenia but also of society...
  13. ncbi Issues in psychopharmacology
    John M Kane
    The Zucker Hillside Hospital Glen Oaks, New York, NY, USA
    Schizophr Bull 34:258. 2008
  14. ncbi Unanswered questions in schizophrenia clinical trials
    John M Kane
    The Zucker Hillside Hospital, Glen Oaks, New York, NY, USA
    Schizophr Bull 34:302-9. 2008
  15. ncbi Review of treatments that can ameliorate nonadherence in patients with schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 67:9-14. 2006
    ....
  16. ncbi Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine
    John M Kane
    Zucker Hillside Hospital and The Albert Einstein College of Medicine, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 68:213-23. 2007
    ..Treatment-resistant schizophrenia poses a major therapeutic challenge. This multicenter, double-blind, randomized study compared the efficacy and safety of aripiprazole and perphenazine in treatment-resistant patients with schizophrenia...
  17. ncbi Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
    John M Kane
    The Zucker Hillside Hospital and The Albert Einstein College of Medicine, Glen Oaks, New York, USA
    Int Clin Psychopharmacol 21:21-8. 2006
    ..Ziprasidone was associated with a greater decrease in median prolactin levels and a lower incidence of clinically significant weight change. Neither agent caused any clinically important changes in QTc interval...
  18. ncbi A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004 1150, USA
    J Clin Psychiatry 70:572-81. 2009
    ..To evaluate the effectiveness of olanzapine versus aripiprazole in patients with schizophrenia...
  19. ncbi Treatment models and designs for intervention research during the psychotic prodrome
    John M Kane
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Schizophr Bull 29:747-56. 2003
    ..Finally, the methodology of completed and ongoing intervention trials in putative prodromal populations is discussed...
  20. ncbi Akathisia: an updated review focusing on second-generation antipsychotics
    John M Kane
    The Zucker Hillside Hospital, Department of Psychiatry, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 70:627-43. 2009
    ..Also, to provide a review of the literature on the incidence of drug-induced akathisia associated with the use of second-generation antipsychotics (SGAs) and first-generation antipsychotics (FGAs)...
  21. ncbi A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, 75 59 263rd St, Kaufmann Bldg, Ste 103, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 72:349-55. 2011
    ..Long-term efficacy of asenapine in preventing schizophrenia relapse was assessed in a 26-week double-blind, placebo-controlled trial that followed 26 weeks of open-label treatment...
  22. ncbi Strategies for making an accurate differential diagnosis of schizoaffective disorder
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York, USA
    J Clin Psychiatry 71:4-7. 2010
    ..Careful documentation of symptoms and recording of the basis for diagnosis are crucial so that the diagnosis can be reevaluated over time...
  23. ncbi Pharmacologic treatment of schizophrenia
    John M Kane
    Zucker Hillside Hospital, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Dialogues Clin Neurosci 12:345-57. 2010
    ..Moreover, new treatment options are needed that affect nondopaminergic targets with relevance for symptom reduction, relapse prevention, enhanced efficacy for nonresponders, and reduced key adverse effects...
  24. ncbi Past and present progress in the pharmacologic treatment of schizophrenia
    John M Kane
    Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 71:1115-24. 2010
    ....
  25. ncbi Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004 1150, USA
    J Clin Psychiatry 71:1475-81. 2010
    ..To evaluate the efficacy and tolerability of armodafinil, the longer-lasting isomer of modafinil, as adjunctive therapy in patients with schizophrenia...
  26. ncbi A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, 75 59 263rd St, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 72:194-204. 2011
    ..The objective of this study was to examine the efficacy and safety of sertindole, compared to risperidone, in this patient population...
  27. ncbi Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Clin Psychopharmacol 30:106-15. 2010
    ..Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms...
  28. ncbi Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials
    John M Kane
    The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    J Psychopharmacol 24:1019-29. 2010
    ..In conclusion, akathisia with aripiprazole occurred early in treatment, was mild-to-moderate in severity, led to few study discontinuations, and did not compromise therapeutic efficacy...
  29. ncbi Creating a health care team to manage chronic medical illnesses in patients with severe mental illness: the public policy perspective
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, 75 59 263rd St, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 70:37-42. 2009
    ..Mental health providers should help improve the integration of primary care and mental health care and implement treatment strategies for changing modifiable health risk factors in their patients with severe mental illness...
  30. ncbi Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 64:19-25. 2003
    ..Available clinical data support rapid titration to > or = 120 mg/day for optimal efficacy in patients with acute exacerbation of schizophrenia...
  31. ncbi Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 64:3-5. 2003
  32. ncbi Commentary: consensus statement on negative symptoms
    John Kane
    Schizophr Bull 32:223-4. 2006
  33. ncbi Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York 11004, USA
    Appl Health Econ Health Policy 7:109-19. 2009
    ..Since their introduction, second-generation antipsychotics (SGAs) have become the drugs of choice for the treatment of schizophrenia. However, recent findings have questioned the benefits of SGAs over first-generation antipsychotics (FGAs)...
  34. ncbi Clinical guideline recommendations for antipsychotic long-acting injections
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, 75 59 263 Street, Glen Oaks, NY 11004, USA
    Br J Psychiatry Suppl 52:S63-7. 2009
    ..Long-acting injections (LAIs) of antipsychotic drugs were developed over 40 years ago in an attempt to improve the long-term treatment of schizophrenia...
  35. ncbi A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004 1150, USA
    J Clin Psychiatry 70:1348-57. 2009
    ..Combining antipsychotics is common practice in the treatment of schizophrenia. This study investigated aripiprazole adjunctive to risperidone or quetiapine for treating schizophrenia and schizoaffective disorder...
  36. ncbi Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Terry E Goldberg
    Zucker Hillside Hospital, 7559 263rd Street, Glen Oaks, NY 11004, USA
    Arch Gen Psychiatry 64:1115-22. 2007
    ..However, none of these studies included healthy controls undergoing repeated testing to assess the possibility that improvements might reflect simple practice effects...
  37. ncbi DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia
    Philip R Szeszko
    Feinstein Institute for Medical Research, Manhasset, NY, USA
    Biol Psychol 79:103-10. 2008
    ..Given that DISC1 plays a role in cerebral cortex development, polymorphisms in this gene may have relevance for neurobiological models of schizophrenia that have implicated cortical deficits in its pathophysiology...
  38. ncbi Patterns of stress in schizophrenia
    Julia D Betensky
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Psychiatry Res 160:38-46. 2008
    ....
  39. ncbi Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    John M Kane
    Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 63:763-71. 2002
    ..CONCLUSION: Aripiprazole, effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder...
  40. ncbi Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks
    John M Kane
    The Zucker Hillside Hospital, 75 59 263 St, Glen Oaks, NY 11004, USA
    Schizophr Res 95:143-50. 2007
    ..This analysis examined symptomatic remission in acutely ill patients with schizophrenia receiving either aripiprazole or haloperidol for one year...
  41. ncbi The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia
    Pamela DeRosse
    Center for Translational Psychiatry, The Feinstein Institute for Medical Research, Manhasset, NY, USA
    Schizophr Bull 34:1047-53. 2008
    ..We examined these chromosomal regions for association to positive, negative, and disorganized symptom clusters, using a dense set of single-nucleotide polymorphisms (SNPs)...
  42. ncbi Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, United States
    Schizophr Res 89:91-100. 2007
    ..To determine whether the coprescribing of two or more antipsychotics, a relatively frequent practice with little data to support its safety and efficacy, is associated with an increased prevalence of metabolic syndrome...
  43. ncbi Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York 11004, USA
    J Child Adolesc Psychopharmacol 18:475-90. 2008
    ....
  44. ncbi Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia
    Pamela DeRosse
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York 11004, USA
    Biol Psychiatry 61:1208-10. 2007
    ....
  45. ncbi Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability
    Katherine E Burdick
    Hillside Hospital, North Shore Long Island Jewish Health System, Department of Psychiatry Research, Glen Oaks, NY 11004, USA
    Am J Psychiatry 167:436-43. 2010
    ..Thus, MET may be of particular interest as a candidate gene for neuropsychiatric diseases with a developmental etiology, including schizophrenia...
  46. ncbi Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia
    Philip R Szeszko
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Neuropsychopharmacology 33:976-84. 2008
    ..These abnormalities have clinical and neuropsychological correlates, which may be useful in further characterizing structure-function relations in schizophrenia and constraining neurobiological models of the disorder...
  47. ncbi Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome
    Christoph U Correll
    Albert Einstein College of Medicine, Department of Psychiatry, Bronx, NY, USA
    Schizophr Bull 33:703-14. 2007
    ..The presence and specificity of a bipolar prodrome remains questioned. We aimed to characterize the prodrome prior to a first psychotic and nonpsychotic mania and to examine the phenotypic proximity to the schizophrenia prodrome...
  48. ncbi White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study
    Philip R Szeszko
    The Zucker Hillside Hospital, Department of Psychiatry Research, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 162:602-5. 2005
    ..The goal of this study was to investigate brain white matter abnormalities by using diffusion tensor imaging in patients with schizophrenia or schizoaffective disorder close to illness onset...
  49. ncbi Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?
    Juan A Gallego
    The Zucker Hillside Hospital, NY 11004, USA
    J Clin Psychiatry 72:1691-6. 2011
    ..This analysis explored trial duration with first-episode patients and asked whether early limited improvement predicts ultimate lack of treatment response with first-episode patients as it does with multiepisode patients...
  50. ncbi Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?
    Anil K Malhotra
    Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, and Albert Einstein College of Medicine, United States
    Schizophr Res 87:181-4. 2006
    ..We tested the hypothesis that ziprasidone improves cognition in the absence of clinical improvement...
  51. ncbi Obesity and coronary risk in patients treated with second-generation antipsychotics
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, 75 59 263rd Street, Glen Oaks, NY, 11004, USA
    Eur Arch Psychiatry Clin Neurosci 261:417-23. 2011
    ..Obesity does not appear to be an independent predictor for the 10-year risk of coronary heart disease events in patients without metabolic syndrome treated with second-generation antipsychotics...
  52. ncbi DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients
    Todd Lencz
    Department of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    Am J Psychiatry 163:529-31. 2006
    ....
  53. ncbi DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia
    Todd Lencz
    Division of Psychiatry Research, The Zucker Hillside Hospital, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Pharmacogenet Genomics 20:569-72. 2010
    ..Given earlier evidence that deletion carriers show reduced symptom response to medication, additional study of appropriate treatment options for these patients seems warranted...
  54. ncbi Dysbindin genotype and negative symptoms in schizophrenia
    Pamela DeRosse
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Am J Psychiatry 163:532-4. 2006
    ....
  55. ncbi Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents
    Christoph U Correll
    Zucker Hillside Hospital, Psychiatry Research, North Shore Long Island Jewish Health System, 75 59 263rd St, Glen Oaks, NY 11004, USA
    JAMA 302:1765-73. 2009
    ..Cardiometabolic effects of second-generation antipsychotic medications are concerning but have not been sufficiently studied in pediatric and adolescent patients naive to antipsychotic medication...
  56. ncbi Quantifying clinical relevance in the treatment of schizophrenia
    Christoph U Correll
    Zucker Hillside Hospital, Psychiatry Research, North Shore Long Island Jewish Health System, Glen Oaks, New York, USA
    Clin Ther 33:B16-39. 2011
    ..While in research studies, the use of quantitative assessments is ubiquitous, this is not the case in routine clinical practice, creating an important translational practice gap...
  57. ncbi Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study
    Christoph U Correll
    North Shore Long Island Jewish Health System, The Zucker Hillside Hospital, Glen Oaks, New York 11004, USA
    J Child Adolesc Psychopharmacol 21:365-8. 2011
    ..The rate-corrected QT interval (QTc) prolongation is a risk factor for sudden cardiac death and may be induced by antipsychotic drugs...
  58. ncbi Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies
    Christoph U Correll
    Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Schneider Children s Hospital, Glen Oaks, NY 11004, USA
    Am J Psychiatry 161:414-25. 2004
    ..This hypothesis was examined in a systematic review of studies involving open or controlled treatment with any second-generation antipsychotic...
  59. ncbi The effects of clozapine and risperidone on spatial working memory in schizophrenia
    Susan R McGurk
    Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Pl, New York, NY 10029, USA
    Am J Psychiatry 162:1013-6. 2005
    ..The purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia...
  60. ncbi Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia
    Todd Lencz
    Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Proc Natl Acad Sci U S A 104:19942-7. 2007
    ..Other risk ROHs feature haplotypes that are also common in healthy individuals, possibly indicating a source of balancing selection...
  61. ncbi Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes
    Delbert G Robinson
    Department of Psychiatry, The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Am J Psychiatry 163:2096-102. 2006
    ..The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders...
  62. ncbi Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes
    Todd Lencz
    The Zucker Hillside Hospital, Psychiatry Research, 75 59 263rd Street, Glen Oaks, New York 11004, USA
    Br J Psychiatry 194:313-8. 2009
    ..Brain-derived neurotrophic factor variants may help clarify the status of schizoaffective disorder...
  63. ncbi White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study
    Sanjiv Kumra
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Am Acad Child Adolesc Psychiatry 44:934-41. 2005
    ..To investigate abnormalities in the structural integrity of brain white matter as suggested by diffusion tensor imaging in adolescents with early-onset schizophrenia (onset of psychosis by age 18)...
  64. ncbi COMT genotype and manic symptoms in schizophrenia
    Pamela DeRosse
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, 75 59 263rd Street, Glen Oaks, NY 11004, and Harvard Partners Center for Genetics and Genomics, Boston, MA, United States
    Schizophr Res 87:28-31. 2006
    ..These data suggest that the effect of COMT variation may be associated with comorbid manic symptoms in SZ...
  65. ncbi Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia
    Philip R Szeszko
    Department of Psychiatry Research, The Zucker Hillside Hospital, 75 59 263rd St, Glen Oaks, NY 11004, USA
    Am J Psychiatry 160:2190-7. 2003
    ..The authors investigated volumetric alterations of the anterior hippocampal formation in patients experiencing a first episode of schizophrenia relative to healthy comparison subjects...
  66. ncbi Early identification and high-risk strategies for bipolar disorder
    Christoph U Correll
    The Zucker Hillside Hospital, Psychiatry Research, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Bipolar Disord 9:324-38. 2007
    ..To describe and compare the relative merits of different identification strategies for individuals at risk for bipolar disorder (BPD)...
  67. ncbi Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
    John M Kane
    The Zucker Hillside Hospital, New York, NY 11004, USA
    Am J Psychiatry 160:1125-32. 2003
    ..CONCLUSIONS: Long-acting injectable risperidone was efficacious and well tolerated and provides both clinicians and patients with a new mode of treatment that can improve the outcome of long-term therapy...
  68. ncbi Clinical insights into pharmacogenetics and schizophrenia, part 2
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 69:1006-13. 2008
  69. ncbi Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, 260 Stetson St, Suite 3224, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 70:4-46. 2009
    ..Summit faculty member opinion is compared with field survey results, and recommendations are made for future research...
  70. ncbi Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    J Clin Psychiatry 67:575-83. 2006
    ....
  71. ncbi Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies
    John M Kane
    Albert Einstein College of Medicine, Bronx, NY, USA
    J Clin Psychiatry 64:34-40. 2003
    ....
  72. ncbi Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data
    Roy H Perlis
    Department of Psychiatry, Massachusetts General Hospital, 50 Staniford Street, Boston, MA 02114, USA
    Am J Psychiatry 159:1155-9. 2002
    ..To assess the effect of abrupt change in lithium dose, the authors reanalyzed data from a previously reported, randomized, double-blind trial of standard- versus low-dose lithium for maintenance therapy in bipolar disorder...
  73. ncbi Metabolic effects of treatment with atypical antipsychotics
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 65:1447-55. 2004
  74. ncbi Reduced frontal white matter integrity in early-onset schizophrenia: a preliminary study
    Sanjiv Kumra
    Department of Research, Zucker Hillside Hospital, Glen Oaks, New York 11004, USA
    Biol Psychiatry 55:1138-45. 2004
    ..Abnormalities found in this study were similar to those reported in adults with chronic schizophrenia. Additional studies are needed to assess whether there is progression of WM abnormalities in schizophrenia...
  75. ncbi Utilization of long-acting antipsychotic medication in patient care
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, New York, NY, USA
    CNS Spectr 11:1-7; quiz 7-8. 2006
    ..Injectables and long-acting formulations of antipsychotics offer additional benefits in terms of ensuring treatment adherence...
  76. ncbi Remission in schizophrenia: proposed criteria and rationale for consensus
    Nancy C Andreasen
    Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA
    Am J Psychiatry 162:441-9. 2005
    ..These criteria should facilitate research and support a positive, longer-term approach to studying outcome in patients with schizophrenia...
  77. ncbi Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
    John M Kane
    Department of Psychiatry, Zucker Hillside Hospital, USA
    J Clin Psychiatry 67:831-2. 2006
  78. ncbi Treatment adherence and long-term outcomes
    John M Kane
    Behavioral Health Services, North Shore Long Island Jewish Health System, NY, USA
    CNS Spectr 12:21-6. 2007
    ..A number of strategies have been developed to assess and facilitate adherence. The first critical step is clinician awareness of the scope of the problem and consideration of appropriate strategies to address it...
  79. ncbi Sex differences in frontal lobe white matter microstructure: a DTI study
    Philip R Szeszko
    Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Neuroreport 14:2469-73. 2003
    ..Our findings may be indicative of increased directional coherence and/or density of left hemisphere white matter fibers and a leftward asymmetry of this structural integrity among women compared to men...
  80. ncbi Genomics and the future of pharmacotherapy in psychiatry
    Anil K Malhotra
    Division of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
    Int Rev Psychiatry 19:523-30. 2007
    ..These increasingly comprehensive approaches should provide informative data on the genes associated with psychotropic drug response, a critical step towards the ultimate goal of 'personalized' medicine...
  81. ncbi Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia
    Philip R Szeszko
    Zucker Hillside Hospital, Psychiatry Research, 75 59 263rd Street, Glen Oaks, NY 11004, USA
    Br J Psychiatry 190:230-6. 2007
    ..Despite the high prevalence of cannabis use in schizophrenia, few studies have examined the potential relationship between cannabis exposure and brain structural abnormalities in schizophrenia...
  82. ncbi Relapse prevention in patients with schizophrenia
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 69:e11. 2008
    ..To help the patient achieve treatment goals, intervention strategies such as switching medications and implementing psychosocial therapies are considered...
  83. ncbi Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects
    Gwenn S Smith
    Department of Psychiatry Research, Hillside Hospital, Neuroscience Institute of the North Shore Long Island Jewish Health System, Glen Oaks, New York 11004, USA
    Synapse 45:105-12. 2002
    ..Future studies will evaluate how the acute metabolic response to citalopram relates to the metabolic response after chronic treatment in patients with geriatric depression...
  84. ncbi Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials
    Christoph U Correll
    The Zucker Hillside Hospital, Psychiatry Research, Glen Oaks, New York, NY 11004, USA
    Schizophr Bull 35:443-57. 2009
    ..Despite lacking evidence for its safety and efficacy, antipsychotic cotreatment is common in schizophrenia. Objective: To evaluate therapeutic and adverse effects of antipsychotic cotreatment vs monotherapy in schizophrenia...
  85. ncbi Early prediction of antipsychotic response in schizophrenia
    Christoph U Correll
    Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Am J Psychiatry 160:2063-5. 2003
    ..The authors' goal was to examine the predictive value of early symptom changes indicating response to antipsychotic medication in schizophrenia...
  86. ncbi Duration of untreated psychosis and time to treatment response for delusions and hallucinations
    Handan Gunduz-Bruce
    VA Medical Center, Psychiatry Service 118A, 950 Campbell Ave, West Haven, CT 06516, USA
    Am J Psychiatry 162:1966-9. 2005
    ..However, individual psychotic symptoms have not been investigated in this context. The authors examined the relationship between duration of untreated psychosis and time to response for hallucinations and delusions...
  87. ncbi Remission and cognitive ability in a cohort of patients with schizophrenia
    Lars Helldin
    Department of Psychiatry, NU Health Care, SE 461 85 Trollhättan, Sweden
    J Psychiatr Res 40:738-45. 2006
    ..The importance of cognitive performance was studied to decide whether cognitive ability is a contributing factor for achieving remission...
  88. ncbi The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations
    Colin A Hodgkinson
    Section of Human Neurogenetics, Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
    Neuropsychopharmacology 32:190-6. 2007
    ..Neuropsychopharmacology (2007) 32, 190-196. doi:10.1038/sj.npp.1301177; published online 16 August 2006...
  89. ncbi Tardive dyskinesia circa 2006
    John M Kane
    Am J Psychiatry 163:1316-8. 2006
  90. ncbi Clinical implications of Brief Psychiatric Rating Scale scores
    Stefan Leucht
    Klinik fürr Psychiatrie und Psychotherapie derTechnischen Universität München, Klinikum rechts der Isar, Ismaningerstrasse 22, 81675 Munchen, Germany
    Br J Psychiatry 187:366-71. 2005
    ..Despite the widespread use of the Brief Psychiatric Rating Scale (BPRS), the clinical meaning of its total score and cut-off values used to define treatment response are unclear...
  91. ncbi An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
    Christopher D Carlson
    Eli Lilly and Company, Indianapolis, Ind, USA
    J Clin Psychiatry 64:898-906. 2003
    ..040) and significantly shorter among clozapine-treated patients (p =.021). CONCLUSION: This analysis of available data from olanzapine clinical trials lends additional support to olanzapine's favorable EPS profile...
  92. ncbi Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia
    Daniel S Umbricht
    Department of Psychiatric Research, Psychiatric University Hospital, Zurich, Switzerland
    J Clin Psychiatry 63:420-4. 2002
    ..Clinicians would be well served if clinical characteristics could be identified that predict a favorable response to clozapine. A few studies addressing this issue have reported inconsistent results...
  93. ncbi Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675 Munchen, Germany
    Schizophr Res 101:312-9. 2008
    ..To use the degree of response after 2 weeks of treatment to predict non-response at 4 to 6 weeks...
  94. ncbi What does the PANSS mean?
    Stefan Leucht
    Klinik für Psychiatrie und Psychotherapie der TU München Klinikum rechts der Isar, Ismaningerstr 22, 81675 Munchen, Germany
    Schizophr Res 79:231-8. 2005
    ..g. at least 20% or 50% reduction of the baseline score) are as yet unclear. We therefore compared the PANSS with simultaneous ratings of Clinical Global Impressions (CGI)...
  95. ncbi Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia
    Daniel S G Umbricht
    Exploratory Clinical Development, Translational Medicine, Novartis Pharma AG, Basel, Switzerland
    Biol Psychiatry 59:762-72. 2006
    ....
  96. ncbi Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials
    Patrizia A Cavazzoni
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 67:107-13. 2006
    ..The present analysis retrospectively examined olanzapine clinical trial data for incidence of treatment-emergent EPS in patients with either schizophrenia or bipolar disorder...
  97. ncbi Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Biol Psychiatry 57:1543-9. 2005
    ....
  98. ncbi Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia
    Alan Breier
    Lilly Research Laboratories, DC 2128, 1 Corporate Plaza, Indianapolis, IN 46285, USA
    Am J Psychiatry 162:1879-87. 2005
    ..The efficacy and safety of olanzapine were compared with those of ziprasidone...
  99. ncbi Clinical guidelines: Dosing and switching strategies for long-acting risperidone
    Stephen R Marder
    VA Greater Los Angeles Health Care System, West Los Angeles Health Center, and the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
    J Clin Psychiatry 64:41-6. 2003
  100. ncbi The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics
    Brian L Strom
    Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    J Clin Psychiatry 69:114-21. 2008
    ..Ziprasidone has been used to treat schizophrenia since 2000. It is unknown whether its modest QTc-prolonging effect increases cardiovascular event risk...
  101. ncbi The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients
    Larry Alphs
    Schizophr Bull 30:577-86. 2004
    ..Because of the complexity of the design issues, a steering committee, suicide monitoring board, and publication committee were established to assist with their management...

Research Grants23

  1. PROSPECTIVE STUDY OF TARDIVE DYSKINESIA DEVELOPMENT
    John Kane; Fiscal Year: 2001
    ..This strategy will provide a rapid and cost-effective answer to a critical question. ..
  2. PREVENTING MORBIDITY IN FIRST EPISODE SCHIZOPHRENIA
    John Kane; Fiscal Year: 2001
    ..The results will provide a basis for informed treatment choices for clinicians as well as address the crucial question of the potential of the new treatments to improve the longitudinal course of this devastating illness. ..
  3. Treating Refractory Childhood Schizophrenia
    John Kane; Fiscal Year: 2004
    ....
  4. Relapse Prevention Study: Steering and Implementation
    John Kane; Fiscal Year: 2007
    ..The study addresses questions that are unlikely to be studied by pharmaceutical industry sponsors and will generate unique information regarding long-term treatment options for schizophrenia. ..